PLX-51107 by Plexxikon for Graft Versus Host Disease (GVHD): Likelihood of Approval
PLX-51107 is a drug candidate under development by Plexxikon for the treatment of chronic lymphocytic leukemia, acute myeloid leukemia, graft versus host disease (GVHD), high-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasm. It is a small molecule that acts by targeting BRD4.
PLX-51107 is currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.
Link to the original story: https://www.pharmaceutical-technology.com/uncategorized/plx-51107-plexxikon-graft-versus-host-disease-gvhd-likelihood-of-approval-2/
7 Ways to Fix Disk Unknown Not Initialized Issue
Advancing Lunar Exploration with AI and Robotics
Are Nokia smartphones dead? Meet the new HMD brand.
About The Author
boB
Well, hey there! The name's boB, and I hail from the humble town of boBsville. I'm a bit of a jack-of-all-trades, you know? I enjoy tinkering around with gadgets, exploring the great outdoors, and meeting new people. If you have any questions or just want to chat, feel free to hit me up!